A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification

dc.contributor.authorOktay, Kaan
dc.contributor.authorSantaliz-Casiano, Ashlie
dc.contributor.authorPatel, Meera
dc.contributor.authorMarino, Natascia
dc.contributor.authorStomiolo, Anna Maria V.
dc.contributor.authorTorun, Hamdi
dc.contributor.authorAcar, Burak
dc.contributor.authorMadak Erdogan, Zeynep
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2021-08-06T16:21:42Z
dc.date.available2021-08-06T16:21:42Z
dc.date.issued2020
dc.description.abstractBreast cancer is the second leading cause of cancer mortality among women. Mammography and tumor biopsy followed by histopathological analysis are the current methods to diagnose breast cancer. Mammography does not detect all breast tumor subtypes, especially those that arise in younger women or women with dense breast tissue, and are more aggressive. There is an urgent need to find circulating prognostic molecules and liquid biopsy methods for breast cancer diagnosis and reducing the mortality rate. In this study, we systematically evaluated metabolites and proteins in blood to develop a pipeline to identify potential circulating biomarkers for breast cancer risk. Our aim is to identify a group of molecules to be used in the design of portable and low-cost biomarker detection devices. We obtained plasma samples from women who are cancer free (healthy) and women who were cancer free at the time of blood collection but developed breast cancer later (susceptible). We extracted potential prognostic biomarkers for breast cancer risk from plasma metabolomics and proteomics data using statistical and discriminative power analyses. We pre-processed the data to ensure the quality of subsequent analyses, and used two main feature selection methods to determine the importance of each molecule. After further feature elimination based on pairwise dependencies, we measured the performance of logistic regression classifier on the remaining molecules and compared their biological relevance. We identified six signatures that predicted breast cancer risk with different specificity and selectivity. The best performing signature had 13 factors. We validated the difference in level of one of the biomarkers, SCF/KITLG, in plasma from healthy and susceptible individuals. These biomarkers will be used to develop low-cost liquid biopsy methods toward early identification of breast cancer risk and hence decreased mortality. Our findings provide the knowledge basis needed to proceed in this direction.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationOktay, K., Santaliz-Casiano, A., Patel, M., Marino, N., Storniolo, A. M. V., Torun, H., Acar, B., & Madak Erdogan, Z. (2020). A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification. Hormones and Cancer, 11(1), 17–33. https://doi.org/10.1007/s12672-019-00372-3en_US
dc.identifier.urihttps://hdl.handle.net/1805/26340
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.isversionof10.1007/s12672-019-00372-3en_US
dc.relation.journalHormones and Canceren_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectliquid biopsyen_US
dc.subjectbreast cancer risken_US
dc.subjectcirculating biomarkeren_US
dc.titleA Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratificationen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Oktay2020Computational-AAM.pdf
Size:
3.23 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: